Business Context and Reporting Period
This Form 8-K was filed by Ainos, Inc. (AIMD) on October 22, 2024, reporting events occurring on October 16, 2024. The Company is incorporated in Texas and is controlled by Taiwan Carbon Nano Technology Corporation ("TCNT") through its majority interest in Ainos Inc., a Cayman Islands corporation ("Ainos KY"), which holds approximately 62.9% of the voting power as of October 17, 2024.
Key Financial Metrics
This filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a material definitive agreement.
Material Changes and Agreements
On October 16, 2024, Ainos, Inc. and TCNT entered into a Third Addendum to their existing Product Development Agreement. Key changes include:
- Scope Expansion: Addition of co-development, exclusive sales rights, and patent authorization for a nitrogen-oxygen separation machine for certain medical applications.
- Patent Rights: Conversion of the patent grant from non-exclusive use to exclusive use of patents for the Company.
- Financial Terms: A fee of $50,000 per month (plus 5% sales tax) for the exclusive use of patents, effective for one year starting October 16, 2024.
- Future Terms: Payment terms and subsequent licensing methods are subject to future negotiation.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard incorporation by reference of the full agreement text. The agreement is subject to future negotiation regarding payment terms after the initial one-year period.
Investor Verification Checklist
- Verify the full text of the Third Addendum Agreement filed as Exhibit 10.1 for complete legal terms.
- Confirm the specific medical applications covered by the nitrogen-oxygen separation machine.
- Monitor future filings for negotiated payment terms and licensing methods post the initial one-year period.
- Review the impact of the $50,000 monthly fee on the Company's future cash flow and operating expenses.